Foghorn Therapeutics Inc (FHTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $124.12M
Last updated: Nov 17, 2026 at 11:05 AM ET
Foghorn Therapeutics Inc (FHTX) Stock Forecast
Analysts expect Foghorn Therapeutics (FHTX) to earn $0.14 per share in the fiscal year ending Dec 31, 2026, on revenue of $104.56M. Of 10 analysts, 5 rate the stock Buy or Strong Buy, 5 Hold and 0 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 2.50, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 50% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 5 | 50.0% |
| Hold | 5 | 50.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a profit to a loss and revenue estimates fall 94.0%.
- Fiscal year ending Dec 31, 2026
- $0.14
- EPS consensus, revenue $104.56M
- Fiscal year ending Dec 31, 2027
- -$1.11
- EPS consensus, revenue $6.24M
- Next report
- Mar 9, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.14 | $0.14 to $0.14 | 1 | $104.56M | $102.90M to $107.88M | 3 |
| Dec 31, 2027 | -$1.11 | -$2.01 to -$0.67 | 6 | $6.24M | N/A | 8 |
Quarterly Estimates
The EPS consensus rises from -$0.25 for the quarter ending Dec 31, 2026 to -$0.23 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.25 | -$0.32 to -$0.17 | 11 | $2.24M | N/A | 11 |
| Mar 31, 2027 | -$0.23 | -$0.26 to -$0.18 | 3 | $12.50M | $12.50M to $12.50M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 5 upward and 5 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 2 |
| Fiscal year ending Dec 31, 2027 | 4 | 2 |
| Quarter ending Mar 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has turned from a loss of $0.87 to a profit.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.14 | -$0.93 | -$0.93 | -$0.88 | -$0.87 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.11 | -$1.03 | -$1.03 | -$1.09 | -$1.03 | N/A |
| Quarter ending Mar 31, 2027 | -$0.23 | -$0.24 | -$0.24 | -$0.27 | -$0.27 | N/A |
Frequently Asked Questions About FHTX
What is the FHTX stock forecast?
Consensus analyst estimates put Foghorn Therapeutics's EPS at $0.14 for the fiscal year ending Dec 31, 2026, on revenue of $104.56M. The consensus rating from 10 analysts is Hold.
How do analysts rate FHTX stock?
Of 10 analysts covering Foghorn Therapeutics, 0 rate it Strong Buy, 5 Buy, 5 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from FHTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.14, with estimates from $0.14 to $0.14 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.11, with estimates from -$2.01 to -$0.67 from 6 analysts.
What revenue do analysts expect from Foghorn Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $104.56M, with estimates from $102.90M to $107.88M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $6.24M.
How many analysts cover FHTX?
10 analysts rate Foghorn Therapeutics stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
FHTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors